NYSE$TDOC
Teladoc Health Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported strong financial results, citing sustained momentum across its diversified portfolio.
Teladoc Health reported an 85% year-over-year revenue growth to $241.0 million for Q2 2020, with total visits increasing by 203% to 2.8 million. The company issued Q3 guidance, raised full-year expectations, and provided a preliminary 2021 revenue growth outlook.
- Q2 revenue grew 85% year-over-year to $241.0 million.
- Total visits increased 203% year-over-year to 2.8 million.
- InTouch Health acquisition solidified leadership in hospital-based telemedicine and is projected to grow over 35% in 2020.
- Utilization stabilized at a level 40 percent higher than before COVID.
Headline financials
Revenue & EPS history
Teladoc · Revenue · Quarterly
$241M
Revenue by segment
Teladoc · $241M total across 2 segments · Q2 2020
- Integrated Care$182M—75.6%
- BetterHelp$58.9M—24.4%
Forward guidance
Teladoc Health provided guidance based on current market conditions and expectations. For the third-quarter 2020, the company expects total revenue to be in the range of $275 million to $285 million and total visits to be between 2.5 million and 2.7 million.
Tailwinds
- Total revenue to be in the range of $275 million to $285 million.
- EBITDA to be in the range of $(3) million to $1 million.
- Adjusted EBITDA to be in the range of $27 million to $31 million.
- Total U.S. paid membership to be approximately 50 million to 51 million members and visit-fee-only access to be available to approximately 21 to 22 million individuals, including 2 to 3 million members on a temporary basis.
- Total visits to be between 2.5 million and 2.7 million.
Headwinds
- Net loss per share, based on 83.4 million weighted average shares outstanding, to be between $(0.35) and $(0.30).
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-1.2%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-1.6%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+23.7%
Q2 2023
Best reaction
-42.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | +11.9% | +27.9% | |
| Q4 2025 | +15.5% | +9.7% | +10.5% | |
| Q3 2025 | +6.2% | -3.0% | -7.8% | |
| Q1 2025 | -2.8% | -5.7% | -3.8% | |
| Q4 2024 | -13.6% | -16.3% | -26.4% | |
| Q3 2024 | +0.9% | -0.6% | +34.3% | |
| Q2 2024 | -11.7% | -21.9% | -26.3% | |
| Q1 2024 | -5.2% | -7.1% | -16.4% | |
| Q4 2023 | -25.6% | -31.1% | -27.3% | |
| Q3 2023 | -3.3% | -13.5% | -5.3% | |
| Q2 2023 | +23.7% | +20.9% | -6.1% | |
| Q1 2023 | +3.4% | +2.2% | -14.4% | |
| Q4 2022 | -3.9% | -5.4% | -12.2% | |
| Q3 2022 | +6.4% | +10.8% | +3.2% | |
| Q2 2022 | -11.4% | -8.4% | -20.1% | |
| Q1 2022 | -42.0% | -35.7% | -38.1% | |
| Q4 2021 | -5.4% | +8.8% | +6.8% | |
| Q3 2021 | +5.6% | +7.2% | -22.4% | |
| Q2 2021 | +1.4% | -0.9% | -5.5% | |
| Q1 2021 | -10.1% | -14.1% | -20.7% | |
| Q4 2020 | -14.2% | -12.7% | -30.9% | |
| Q3 2020 | -2.3% | -14.6% | -11.9% | |
| Q2 2020 | +11.5% | +11.5% | -1.9% | |
| Q1 2020 | -9.1% | -3.8% | -3.9% | |
| Q4 2019 | +14.1% | +5.1% | +38.6% | |
| Q3 2019 | +7.1% | +12.3% | +17.1% | |
| Q2 2019 | +1.9% | -6.5% | -17.5% | |
| Q1 2019 | -2.0% | +2.9% | -1.8% | |
| Q4 2018 | -4.5% | -6.3% | -17.5% | |
| Q3 2018 | +4.6% | -8.6% | -9.9% | |
| Q2 2018 | +9.0% | +10.3% | +29.6% | |
| Q1 2018 | +5.7% | -1.9% | +18.4% | |
| Q4 2017 | +4.0% | +8.8% | +4.5% | |
| Q3 2017 | -3.0% | -5.4% | +8.0% | |
| Q2 2017 | -7.1% | -2.6% | +5.5% | |
| Q1 2017 | +23.3% | +26.9% | +46.3% | |
| Q4 2016 | +6.8% | -4.8% | +13.4% | |
| Q3 2016 | +6.2% | +8.6% | +19.4% | |
| Q2 2016 | -16.1% | -9.0% | +2.9% | |
| Q1 2016 | -1.5% | — | — | |
| Q4 2015 | -7.3% | — | — | |
| Q3 2015 | -10.6% | — | — | |
| Q2 2015 | +3.6% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro